1. Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)‏
by Gert J. Ossenkoppele, Georg Stussi, Johan Maertens, Kees van Montfort, Bart J. Biemond, Dimitri Breems, August Ferrant, Carlos Graux, Georgine E. de Greef, C. J. M. Halkes, Mels Hoogendoorn, Rene M. Hollestein, Mojca Jongen-Lavrencic, Mark D. Levin, Arjan A. van de Loosdrecht, Marinus van Marwijk Kooij, Yvette van Norden, Thomas Pabst, Harry C. Schouten, Edo Vellenga, Gregor E. G. Verhoef, Okke de Weerdt, Pierre Wijermans, Jakob R. Passweg, and Bob Löwenberg
Blood
Volume 120(24):
December 6, 2012
©2012 by American Society of Hematology

2. Effect of addition of bevacizumab to a standard regimen of daunorubicin and cytarabine-arabinoside.
Effect of addition of bevacizumab to a standard regimen of daunorubicin and cytarabine-arabinoside. Shown are EFS (A) and OS (B) in patients 60 years of age or older with AML.
Gert J. Ossenkoppele et al. Blood 2012;120:
©2012 by American Society of Hematology

3. Recovery time in days to achieve a platelet count of > 50 × 109/L.
Recovery time in days to achieve a platelet count of > 50 × 109/L. Cycle 1 is shown in panel A and cycle 2 in panel B.
Gert J. Ossenkoppele et al. Blood 2012;120:
©2012 by American Society of Hematology